Prospective Outcomes of Arthroscopic Acetabular Labral Repair With and Without Bone Marrow Aspirate Concentrate Application

What this Trial Is About

Researchers are evaluating the use of bone marrow aspirate concentrate (BMAC) combined with hip arthroscopy to treat patients with femoro-acetabular impingement (FAI) and acetabular labral tears. FAI can damage the acetabular labrum and the chondrolabral junction, potentially accelerating hip osteoarthritis. This study aims to compare outcomes after arthroscopic labral repair with and without BMAC application to address early cartilage damage and improve joint biomechanics. The study involves adult patients diagnosed with labral tears and pincer or cam deformities who undergo arthroscopic labral repair using a capsular chondrolabral preservation technique. During surgery, the decision to apply BMAC, which involves aspirating bone marrow, concentrating mesenchymal stromal cells, and injecting them into the hip joint, is made based on intra-operative findings. Patients either receive BMAC treatment or standard arthroscopic repair without BMAC. Follow-up visits are scheduled at 3 months, 6 months, 12 months, and then annually to monitor progress. Participants will complete surveys measuring hip function and pain, such as iHOT-33, HOS, NAHS, LEFS, mHHS, RAND-36, and pain visual analog scales before surgery and at follow-up visits. Patient satisfaction questionnaires are collected at 12 months and annually. The study also involves standard diagnostic imaging and clinical exams for diagnosis and eligibility. The total duration of participation varies as patients are monitored long term after surgery to assess outcomes and safety.

Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear